Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure

Madonna, Rosalinda; Laake, Linda W. van; Davidson, Sean M.; Engel, Felix B.; Hausenloy, Derek J.; Lecour, Sandrine; Leor, Jonathan; Perrino, Cinzia; Schulz, Rainer; Ytrehus, Kirsti; Landmesser, Ulf; Mummery, Christine L.; Janssens, Stefan; Willerson, James T.; Eschenhagen, Thomas; Ferdinándy, Péter; Sluijter, Joost P.G.

doi:10.1093/eurheartj/ehw113

Cited by 215 publications

(233 citation statements)

References 188 publications

Supporting

Mentioning

231

Contrasting

Order By: Relevance

“…This finding clearly demands the implementation of personalized cardiac SC therapies in which the selection of SC source, modification and application is subjected to these individual characteristics [525]. Thus, prospective research should focus on the development of specific responder scores and the identification of prognostic biomarkers to identify patient cohorts who benefit most from distinct SC treatments [526,527]. Thereby, a higher standardization of study designs and the establishment of a global open-access database for the registration and publication of preclinical and clinical trials would greatly improve the comparability and access of obtained data [526,528,529].…”

Section: Resultsmentioning

confidence: 99%

Stem Cell Therapy in Heart Diseases – Cell Types, Mechanisms and Improvement Strategies

Müller

Lemcke

Dávid

2018

Cell Physiol Biochem

161

133

View full text Add to dashboard Cite

A large number of clinical trials have shown stem cell therapy to be a promising therapeutic approach for the treatment of cardiovascular diseases. Since the first transplantation into human patients, several stem cell types have been applied in this field, including bone marrow derived stem cells, cardiac progenitors as well as embryonic stem cells and their derivatives. However, results obtained from clinical studies are inconsistent and stem cell-based improvement of heart performance and cardiac remodeling was found to be quite limited. In order to optimize stem cell efficiency, it is crucial to elucidate the underlying mechanisms mediating the beneficial effects of stem cell transplantation. Based on these mechanisms, researchers have developed different improvement strategies to boost the potency of stem cell repair and to generate the “next generation” of stem cell therapeutics. Moreover, since cardiovascular diseases are complex disorders including several disease patterns and pathologic mechanisms it may be difficult to provide a uniform therapeutic intervention for all subgroups of patients. Therefore, future strategies should aim at more personalized SC therapies in which individual disease parameters influence the selection of optimal cell type, dosage and delivery approach.

show abstract

Section: Resultsmentioning

confidence: 99%

Stem Cell Therapy in Heart Diseases – Cell Types, Mechanisms and Improvement Strategies

Müller

Lemcke

Dávid

2018

Cell Physiol Biochem

161

133

View full text Add to dashboard Cite

show abstract

“…However, the benefits of SCs have been attributed to their paracrine effects, which could be mediated by exosomes[64,72]. Following the observation that the SCs remain at the site of injection release factors mediating this paracrine effect, exosomes have been proposed as important potential paracrine mediators for myocardial regeneration.…”

Section: Exosomes As Emerging Tools For Post-myocardial Infarction Rementioning

confidence: 99%

Stem cell-derived exosomes - an emerging tool for myocardial regeneration

Lázár

Benedek

Korodi

et al. 2018

WJSC

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs) continue to represent the number one cause of death and disability in industrialized countries. The most severe form of CVD is acute myocardial infarction (AMI), a devastating disease associated with high mortality and disability. In a substantial proportion of patients who survive AMI, loss of functional cardiomyocytes as a result of ischaemic injury leads to ventricular failure, resulting in significant alteration to quality of life and increased mortality. Therefore, many attempts have been made in recent years to identify new tools for the regeneration of functional cardiomyocytes. Regenerative therapy currently represents the ultimate goal for restoring the function of damaged myocardium by stimulating the regeneration of the infarcted tissue or by providing cells that can generate new myocardial tissue to replace the damaged tissue. Stem cells (SCs) have been proposed as a viable therapy option in these cases. However, despite the great enthusiasm at the beginning of the SC era, justified by promising initial results, this therapy has failed to demonstrate a significant benefit in large clinical trials. One interesting finding of SC studies is that exosomes released by mesenchymal SCs (MSCs) are able to enhance the viability of cardiomyocytes after ischaemia/reperfusion injury, suggesting that the beneficial effects of MSCs in the recovery of functional myocardium could be related to their capacity to secrete exosomes. Ten years ago, it was discovered that exosomes have the unique property of transferring miRNA between cells, acting as miRNA nanocarriers. Therefore, exosome-based therapy has recently been proposed as an emerging tool for cardiac regeneration as an alternative to SC therapy in the post-infarction period. This review aims to discuss the emerging role of exosomes in developing innovative therapies for cardiac regeneration as well as their potential role as candidate biomarkers or for developing new diagnostic tools.

show abstract

“…Stem cell therapy has been a long pursued strategy in cardiovascular regenerative medicine to counteract cardiomyocyte loss upon MI [87,88]. Efforts to improve myocardial regeneration through stem cell therapy have focused on three major aspects: i) promote stem cell commitment towards cardiac differentiation, ii) ensure exogenous stem cell Remarkably, autophagy appears to be relevant to all of these specific approaches ( Figure 2).…”

Section: Therapeutic Potential Of Autophagy Upon Myocardial Infarctionmentioning

confidence: 99%

Therapeutic targeting of autophagy in myocardial infarction and heart failure

Riquelme

Chávez

Mondaca‐Ruff

et al. 2016

Expert Review of Cardiovascular Therapy

View full text Add to dashboard Cite

PubMed searches were performed to discuss the current state of the art regarding the role of autophagy in MI and HF. We review available and potential approaches to modulate autophagy from a pharmacological and genetic perspective. We also discuss the targeting of autophagy in myocardial regeneration. Expert commentary: The targeting of autophagy has potential for the treatment of MI and HF. Autophagy is a process that takes place in virtually all cells of the body and thus, in order to evaluate this therapeutic approach in clinical trials, strategies that specifically target this process in the myocardium is required to avoid unwanted effects in other organs.

show abstract

Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure

Cited by 215 publications

References 188 publications

Stem Cell Therapy in Heart Diseases – Cell Types, Mechanisms and Improvement Strategies

Stem Cell Therapy in Heart Diseases – Cell Types, Mechanisms and Improvement Strategies

Stem cell-derived exosomes - an emerging tool for myocardial regeneration

Therapeutic targeting of autophagy in myocardial infarction and heart failure

Contact Info

Product

Resources

About